Skip to main content
Log in

Comment on: ‘Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality’

  • Letter to the Editor
  • Published:
International Journal of Impotence Research Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Bischoff E . Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004; 16(Suppl 1): S34–S37.

    Article  CAS  Google Scholar 

  2. Cheitlin MD et al. Use of Sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273–282.

    Article  CAS  Google Scholar 

  3. Kloner RA . Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149–3155.

    Article  Google Scholar 

  4. Gbekor E et al. Selectivity of sildenafil and other phosphodiesterase type 5 inhibitors against all human phosphodiesterase families. Eur Urol 2002; 1(Suppl 1): 63.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J L Weeks II.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weeks, J. Comment on: ‘Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality’. Int J Impot Res 17, 387 (2005). https://doi.org/10.1038/sj.ijir.3901306

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901306

  • Springer Nature Limited

Navigation